Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Cathomas

Showing results (131-140 of 139) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 139 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2021
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update ConsortiumJörg Beyer, Laurence Collette, Nicolas Sauvé, et al.
World Journal of Urology|September 19, 2024
Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic reviewErnest Kaufmann, Stefanie Aeppli, Winfried Arnold, et al.
Bladder Cancer (Amsterdam, Netherlands)|January 19, 2026
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancerErnest Kaufmann, Stefanie Aeppli, Andres Affentranger, et al.
Lancet (London, England)|January 1, 2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D James, Matthew R Sydes, Noel W Clarke, et al.
European Urology Oncology|June 4, 2019
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth S Woods, Eleftherios Sideris, Matthew R Sydes, et al.
Prostate Cancer and Prostatic Diseases|May 28, 2026
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progressionFabio Turco, Silke Gillessen, Giuseppe Salfi, et al.
The Lancet. Oncology|May 4, 2023
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Laura Murphy, Noel W Clarke, et al.
European Urology|May 25, 2020
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]J Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
European Urology|November 23, 2019
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort<sup>†</sup>: Under the Auspices of the EAU-ESMO Guidelines CommitteesJ Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Pageof 14

Showing results (131-140 of 139) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 139 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2021
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update ConsortiumJörg Beyer, Laurence Collette, Nicolas Sauvé, et al.
World Journal of Urology|September 19, 2024
Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic reviewErnest Kaufmann, Stefanie Aeppli, Winfried Arnold, et al.
Bladder Cancer (Amsterdam, Netherlands)|January 19, 2026
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancerErnest Kaufmann, Stefanie Aeppli, Andres Affentranger, et al.
Lancet (London, England)|January 1, 2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D James, Matthew R Sydes, Noel W Clarke, et al.
European Urology Oncology|June 4, 2019
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth S Woods, Eleftherios Sideris, Matthew R Sydes, et al.
Prostate Cancer and Prostatic Diseases|May 28, 2026
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progressionFabio Turco, Silke Gillessen, Giuseppe Salfi, et al.
The Lancet. Oncology|May 4, 2023
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Laura Murphy, Noel W Clarke, et al.
European Urology|May 25, 2020
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]J Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
European Urology|November 23, 2019
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort<sup>†</sup>: Under the Auspices of the EAU-ESMO Guidelines CommitteesJ Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Pageof 14